These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1973057)

  • 21. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
    Butler B; Bech P
    Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine.
    Tamminga CA; Gotts MD; Thaker GK; Alphs LD; Foster NL
    Arch Gen Psychiatry; 1986 Apr; 43(4):398-402. PubMed ID: 2869745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPECT technique for visualization of cerebral dopamine D2 receptors.
    Konig P; Benzer MK; Fritzche H
    Am J Psychiatry; 1991 Nov; 148(11):1607-8. PubMed ID: 1681752
    [No Abstract]   [Full Text] [Related]  

  • 24. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
    Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. D1 and D2 and D3.
    Healy D
    Br J Psychiatry; 1991 Sep; 159():319-24. PubMed ID: 1683592
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
    Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
    Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
    [No Abstract]   [Full Text] [Related]  

  • 27. Maintenance therapy and the natural course of schizophrenia.
    Davis JM
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis.
    van Kammen DP
    Psychol Med; 1991 Nov; 21(4):881-95. PubMed ID: 1685791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased blink rates in schizophrenics. Influences of neuroleptics and psychopathology.
    Mackert A; Flechtner KM; Woyth C; Frick K
    Schizophr Res; 1991; 4(1):41-7. PubMed ID: 1672606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
    Altamura AC
    Schizophr Res; 1993 Jan; 8(3):187-98. PubMed ID: 8094628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
    Chouinard G
    J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3H-spiroperidol binding to human peripheral mononuclear cells: methodological aspects.
    Wodarz N; Fritze J; Kornhuber J; Riederer P
    Biol Psychiatry; 1992 Feb; 31(3):291-303. PubMed ID: 1532133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
    Kerwin RW
    Br J Psychiatry; 1994 Feb; 164(2):141-8. PubMed ID: 7513599
    [No Abstract]   [Full Text] [Related]  

  • 35. Neuroleptic-induced supersensitivity psychosis.
    Chouinard G; Jones BD; Annable L
    Am J Psychiatry; 1978 Nov; 135(11):1409-10. PubMed ID: 30291
    [No Abstract]   [Full Text] [Related]  

  • 36. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 37. 3H-spiperone binding in platelet membranes: a possible biological marker for schizophrenia.
    Sethi BB; Kumar P; Agarwal AK; Seth PK; Trivedi JK
    Acta Psychiatr Scand; 1986 Feb; 73(2):186-90. PubMed ID: 3705995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia.
    Jarema M; Kacperczyk J; Kruszynski S
    Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical antipsychotics.
    Holland D; Watanabe MD; Sharma R
    Psychiatr Med; 1991; 9(1):5-24. PubMed ID: 1673259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is clozapine response different in neuroleptic nonresponders vs partial responders?
    Osser DN; Albert LG
    Arch Gen Psychiatry; 1990 Feb; 47(2):189-90. PubMed ID: 1967927
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.